Economic evaluation of intensive care treatment from a view of safety management
| Project/Area Number |
15590455
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical sociology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
SAKAKIBARA Yoko Nagoya University, University Hospital, Assistant Professor, 医学部附属病院, 助手 (50262910)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2004: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | intensive care / hospital acquired infection / ventilator associated pneumonia / heparin induced thrombocytopenia / economic evaluation / safety management / cost / ヘパリン誘発性血小板減少症 / 患者転帰 |
|---|
| Research Abstract |
As hospital acquired infection, especially ventilator associated pneumonia (VAP), and heparin induced thrombothytopenia (HIT) affects patients outcome and cost in intensive care unit, we collected patients data and investigated correlation of these data.
Concerning to hospital acquired infection, we examined patient's outcome, duration of hospital and ICU stay, ventilated days and cost who had VAP in ICU. There are correlation between duration of hospital stay and outcome, duration of hospital stay and ventilated days, duration of hospital stay and cost. These show that extra cost is caused, because VAP acts on prolonging days on ventilator and hospital stay. Then, not only patients but also hospitals suffer a loss of profits and confidence about hospital management.
Regarding to HIT, as we often give heparin to patients in ICU, it may increase occurrence of HIT. Number of platelets and HIT antibody were measured for the investigation of the prediction of HIT's happening and the possibility of HIT's screening. The HIT antibody did not detect any patient who was diagnosed HIT clinically because of symptoms. There is no compatibility of appearance between antibody and symptoms. It shows it is impossible to predict of occurrence of HIT by examination of HIT antibody, or dose/ way to prescribe heparin. Further, it costs much when the HIT antibody is used as screening to detect HIT.
|
Report
(4 results)
Research Products
(4 results)
